Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 1;195(2):186–193. doi: 10.1111/bjh.17608

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 British Society for Haematology and John Wiley & Sons Ltd

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

Fig 3 — Subgroup analysis of predictors of response according to patients' characteristics. *1, polyclonal immunoglobulin estimated by total globulins minus monoclonal protein; *2, treatment at time of vaccination; *3, number of novel anti‐myeloma drugs exp;osed up to time of vaccination; *4, prior haematopoietic stem cell transplantation. ALC, absolute lymphocyte count; DARA, daratumumab; FISH, fluorescence in situ hybridization; HSCT, haematopoietic stem cell transplantation; Ig, immunoglobulin; IMiD, immunomodulatory; ISS, International Staging System; IVIG, intravenous immunoglobulin; MM,; PI, proteasome inhibitor; PR, partial response; VGPR, very good partial response.